A Phase 3 interventional study of TEV-45779 and XOLAIR® Injection in Chronic Urticaria, sponsored by Teva Pharmaceuticals USA. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 16 under way, 6 of them phase 3. Chronic Urticaria · United States.
Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 8th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2021, is one of 21 in phase 3, and was the 32nd registered.
199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.
Browse Chronic Urticaria studies →9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 25 · Phase 3 22 · Phase 4 4
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 608 is above the median of 80 across 149 interventional studies indexed under Chronic Urticaria.
Median enrollment 132 across the 58 interventional studies, 428 across the 6 observational. Of the 45 that completed or were terminated, 30 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 64 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Pharmaceuticals USA, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 1 study filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
6 of the studies in Chronic Urticaria with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT07540910Enanta Pharmaceuticals, IncA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | 2026-11 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT07408219Novartis PharmaceuticalsA Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients | 2026-12-31 |
| NCT06927999ARS Pharmaceuticals, Inc.An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Chronic Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.
This is a multicenter, randomized, double-blind study to demonstrate similar efficacy and safety of TEV-45779 compared to XOLAIR administered sc at doses of 300 mg or 150 mg every 4 weeks for 24 weeks (6 treatments) in patients with Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite antihistamine (H1) treatment. This study will consist of a screening period (up to 2 weeks), a 24-week treatment period consisting of a 12-week double-blind main treatment period and a 12-week double-blind transition period, which is followed by a 16-week follow-up period. The total duration of the study is up to 42 weeks.
At baseline, patients will be randomized in a 2:2:1:1 ratio to receive the first 3 treatments of TEV-45779 300 mg, XOLAIR 300 mg, TEV-45779 150 mg or XOLAIR 150 mg (main treatment period). At Week 12, prior to receiving their fourth dose of study medication, patients in the XOLAIR 300 mg and the XOLAIR 150 mg treatment groups will be randomized 1:1 to receive 3 additional doses of XOLAIR (at the same dose level as prior to randomization, or switch to 3 doses of TEV-45779 (transition period) at the same dose level as prior to randomization. All patients in the TEV-45779 groups will continue to receive TEV-45779 at the same dose levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
Combination Product: TEV-45779
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
Combination Product: XOLAIR® Injection
TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
Combination Product: TEV-45779
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
Combination Product: XOLAIR® Injection
TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to TEV-45779-300 mg in the Main Treatment period.
Combination Product: TEV-45779
TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
Combination Product: TEV-45779 · Combination Product: XOLAIR® Injection
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
Combination Product: XOLAIR® Injection
TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to TEV-45779-150 mg in the main treatment period.
Combination Product: TEV-45779
TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
Combination Product: TEV-45779 · Combination Product: XOLAIR® Injection
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
Combination Product: XOLAIR® Injection
TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission)
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. Least square (LS) mean and 95% confidence interval (CI) were calculated using analysis of covariance (ANCOVA) model. Multiple imputation performed both for the participants having missing ISS7 at week 12 and for participants using any disallowed concomitant medication.
Time frame: Baseline, Week 12
Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For Food and Drug Administration [FDA] Submission)
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. LS mean and 90% CI were calculated using ANCOVA model. Multiple imputation performed for the participants having missing ISS7 at week 12.
Time frame: Baseline, Week 12
Change From Baseline in the ISS7 at Weeks 4 and 12
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. The observed mean and standard deviation values are reported here with no imputation performed.
Time frame: Baseline, Weeks 4 and 12
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.
Time frame: Baseline, Week 12
Percentage of Participants With a UAS7 Score ≤6 at Week 12
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 is the number of participants achieving the endpoint of less than or equal to 6. UAS7 was calculated as the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.
Time frame: Week 12
Percentage of Complete Responders (UAS7 Score = 0) at Week 12
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms. Complete responders were participants with a UAS7 score = 0.
Time frame: Week 12
Change From Baseline in the Physician's (In-clinic) Assessment of UAS at Week 12
Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.
Time frame: Baseline, Week 12
Change From Baseline in the Weekly Number of Wheals Score at Week 12
The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).
Time frame: Baseline, Week 12
Change From Baseline in the Weekly Size of the Largest Wheals Score at Week 12
The weekly size of the largest wheals score was calculated from the eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 centimeters \[cm\]) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score of 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as the sum of the available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.
Time frame: Baseline, Week 12
Time to Minimally Important Difference (MID) Response in ISS7 Score
Time to MID response was defined as time to a reduction from baseline in ISS7 of ≥5 points in ISS7 score by Week 12.
Time frame: Baseline up to Week 12
Percentage of ISS7 MID Responders at Week 12
A responder was defined as a participant with a reduction from baseline in ISS7 of ≥5 points in ISS7 score.
Time frame: Week 12
Percentage of Angioedema-Free Days From Week 4 to Week 12
Percentage of angioedema-free days from Week 4 to Week 12 were calculated based on the diary data as the number of days in the diary between the dates of Week 4 and Week 12 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.
Time frame: Week 4 to Week 12
Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12
The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.
Time frame: Baseline, Week 12
Change From Week 12 in ISS7 at Weeks 24 and 40
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching.
Time frame: Week 12, Weeks 24 and 40
Change From Week 12 in the UAS7 at Week 24
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which can range from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which can range from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.
Time frame: Week 12, Week 24
Change From Week 12 in the Physician's (In-clinic) Assessment of UAS7 at Week 24
Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.
Time frame: Week 12, Week 24
Change From Week 12 in the Weekly Number of Wheals Score at Weeks 24 and 40
The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).
Time frame: Week 12, Weeks 24 and 40
Change From Week 12 in the Weekly Size of the Largest Wheals Score at Weeks 24 and 40
The weekly size of the largest wheals score was calculated from eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 cm) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as sum of available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.
Time frame: Week 12, Weeks 24 and 40
Percentage of Angioedema-Free Days From Week 12 to Week 24
Percentage of angioedema-free days from Week 12 to Week 24 was calculated based on the diary data as the number of days in the diary between the dates of Week 12 and Week 24 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.
Time frame: Week 12 to Week 24
Change From Week 12 in the Overall DLQI Score at Weeks 24 and 40
The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.
Time frame: Week 12, Weeks 24 and 40
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) in the Main Treatment Period
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Week 12
Number of Participants With at Least One TEAE Week 12 up to Week 24
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Week 12 up to Week 24
Number of Participants With Antidrug Antibodies (ADAs) in the Main Treatment Period
Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.
Time frame: Baseline up to Week 12
Number of Participants With ADAs From Week 12 to Week 24
Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.
Time frame: Week 12 up to Week 24
| Milestone | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 201 | 102 | 203 | 102 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 201 | 102 | 203 | 102 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 188 | 98 | 194 | 101 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 4 | 9 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 3 | 8 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other than specified | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 188 | 98 | 97 | 51 | 97 | 50 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 0 | 188 | 98 | 97 | 51 | 97 | 50 |
| Completed | 0 | 0 | 0 | 0 | 178 | 90 | 93 | 49 | 95 | 47 |
| Not completed | 0 | 0 | 0 | 0 | 10 | 8 | 4 | 2 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 9 | 7 | 4 | 2 | 2 | 3 |
| Withdrew: Other than specified | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. Least square (LS) mean and 95% confidence interval (CI) were calculated using analysis of covariance (ANCOVA) model. Multiple imputation performed both for the participants having missing ISS7 at week 12 and for participants using any disallowed concomitant medication.
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: XOLAIR High Dose |
|---|---|---|
| Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission) | -10.92 ± -11.85 | -10.61 ± -11.51 |
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. LS mean and 90% CI were calculated using ANCOVA model. Multiple imputation performed for the participants having missing ISS7 at week 12.
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: XOLAIR High Dose |
|---|---|---|
| Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For Food and Drug Administration [FDA] Submission) | -10.77 (-11.61 to -9.93) | -10.38 (-11.24 to -9.52) |
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. The observed mean and standard deviation values are reported here with no imputation performed.
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Change at Week 4 | -7.64 ± 6.383 | -7.35 ± 6.236 | -7.87 ± 6.033 | -7.27 ± 6.084 |
| Change at Week 12 | -10.92 ± 6.512 | -9.96 ± 6.340 | -10.65 ± 6.490 | -10.35 ± 6.082 |
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 | -22.10 ± 13.204 | -20.67 ± 12.223 | -21.73 ± 12.651 | -21.67 ± 12.158 |
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 is the number of participants achieving the endpoint of less than or equal to 6. UAS7 was calculated as the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.
| percentage of participants | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Percentage of Participants With a UAS7 Score ≤6 at Week 12 | 49.5 | 45.8 | 46.4 | 48.5 |
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms. Complete responders were participants with a UAS7 score = 0.
| percentage of participants | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Percentage of Complete Responders (UAS7 Score = 0) at Week 12 | 33.2 | 28.1 | 29.6 | 30.9 |
Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Change From Baseline in the Physician's (In-clinic) Assessment of UAS at Week 12 | -3.38 ± 2.002 | -3.34 ± 1.907 | -3.55 ± 1.893 | -3.15 ± 2.085 |
The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Change From Baseline in the Weekly Number of Wheals Score at Week 12 | -11.18 ± 7.127 | -10.70 ± 6.551 | -11.09 ± 6.740 | -11.33 ± 6.672 |
The weekly size of the largest wheals score was calculated from the eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 centimeters \[cm\]) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score of 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as the sum of the available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Change From Baseline in the Weekly Size of the Largest Wheals Score at Week 12 | -10.28 ± 6.937 | -9.52 ± 6.670 | -10.45 ± 6.745 | -10.68 ± 6.838 |
Time to MID response was defined as time to a reduction from baseline in ISS7 of ≥5 points in ISS7 score by Week 12.
| weeks | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Time to Minimally Important Difference (MID) Response in ISS7 Score | 2.0 (2.0 to 3.0) | 2.0 (1.0 to 2.0) | 2.0 (NA to NA) | 2.0 (2.0 to 3.0) |
A responder was defined as a participant with a reduction from baseline in ISS7 of ≥5 points in ISS7 score.
| percentage of participants | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Percentage of ISS7 MID Responders at Week 12 | 81.0 | 78.1 | 80.6 | 79.4 |
Percentage of angioedema-free days from Week 4 to Week 12 were calculated based on the diary data as the number of days in the diary between the dates of Week 4 and Week 12 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.
| percentage of days | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Percentage of Angioedema-Free Days From Week 4 to Week 12 | 100.00 ± 0.0 | 100.00 ± 0.0 | 100.00 ± 0.0 | 100.00 ± 0.0 |
The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.
| units on a scale | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12 | -9.72 ± 7.125 | -8.40 ± 7.28 | -9.54 ± 7.091 | -8.09 ± 6.432 |
The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching.
| units on a scale | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Change at Week 24 | -1.64 ± 3.598 | -1.37 ± 4.576 | -1.82 ± 4.016 | -1.21 ± 3.186 | -1.78 ± 4.226 | -2.09 ± 4.585 |
| Change at Week 40 | 1.84 ± 7.182 | 0.44 ± 6.982 | 1.43 ± 6.870 | 1.58 ± 5.274 | 2.03 ± 7.969 | 1.27 ± 6.718 |
The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which can range from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which can range from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.
| units on a scale | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Change From Week 12 in the UAS7 at Week 24 | -3.37 ± 6.641 | -2.66 ± 9.524 | -3.65 ± 7.953 | -2.54 ± 7.546 | -3.45 ± 8.387 | -3.12 ± 9.419 |
Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.
| units on a scale | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Change From Week 12 in the Physician's (In-clinic) Assessment of UAS7 at Week 24 | -0.55 ± 1.556 | -0.40 ± 2.032 | -0.27 ± 1.360 | -0.53 ± 1.838 | -0.38 ± 1.413 | -0.67 ± 1.548 |
The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).
| units on a scale | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Change at Week 24 | -1.73 ± 3.649 | -1.29 ± 5.262 | -1.84 ± 4.139 | -1.33 ± 4.793 | -1.67 ± 4.510 | -1.03 ± 5.281 |
| Change at Week 40 | 1.87 ± 7.412 | 0.60 ± 8.236 | 1.53 ± 6.953 | 2.05 ± 6.110 | 2.77 ± 8.620 | 2.13 ± 7.809 |
The weekly size of the largest wheals score was calculated from eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 cm) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as sum of available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.
| units on a scale | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Change at Week 24 | -1.87 ± 3.898 | -1.28 ± 4.697 | -1.78 ± 4.334 | -1.18 ± 4.464 | -1.94 ± 4.776 | -0.88 ± 4.456 |
| Change at Week 40 | 1.46 ± 7.434 | 0.72 ± 7.899 | 1.34 ± 7.332 | 2.35 ± 5.968 | 2.71 ± 8.706 | 1.87 ± 7.798 |
Percentage of angioedema-free days from Week 12 to Week 24 was calculated based on the diary data as the number of days in the diary between the dates of Week 12 and Week 24 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.
| percentage of days | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Percentage of Angioedema-Free Days From Week 12 to Week 24 | 100.00 ± 0.0 | 100.00 ± 0.0 | 100.00 ± 0.0 | 100.00 ± 0.0 | 100.00 ± 0.0 | 100.00 ± 0.0 |
The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.
| units on a scale | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Change at Week 24 | -1.44 ± 3.621 | -0.43 ± 5.619 | -1.19 ± 4.387 | -1.82 ± 5.552 | -0.88 ± 4.788 | -1.60 ± 4.271 |
| Change at Week 40 | 1.65 ± 7.581 | 1.05 ± 7.545 | 0.51 ± 7.096 | 0.39 ± 5.098 | 2.45 ± 7.791 | 1.10 ± 7.570 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) in the Main Treatment Period | 64 | 37 | 71 | 33 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Number of Participants With at Least One TEAE Week 12 up to Week 24 | 78 | 34 | 43 | 18 | 38 | 16 |
Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.
| Participants | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose |
|---|---|---|---|---|
| Positive | 18 | 6 | 37 | 13 |
| Positive, Not Treatment Related | 8 | 5 | 5 | 4 |
| Negative | 173 | 90 | 159 | 85 |
Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.
| Participants | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|
| Positive | 34 | 15 | 10 | 4 | 14 | 8 |
| Positive, Not Treatment Related | 6 | 4 | 3 | 1 | 1 | 2 |
| Negative | 142 | 76 | 83 | 45 | 81 | 38 |
Collected over Baseline up to Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Treatment Period: TEV-45779 High Dose | 0/201 (0%) | 1/201 (0.5%) | 30/201 (14.9%) |
| Main Treatment Period: TEV-45779 Low Dose | 0/102 (0%) | 0/102 (0%) | 19/102 (18.6%) |
| Main Treatment Period: XOLAIR High Dose | 0/203 (0%) | 3/203 (1.5%) | 30/203 (14.8%) |
| Main Treatment Period: XOLAIR Low Dose | 0/102 (0%) | 0/102 (0%) | 10/102 (9.8%) |
| Transition Period: TEV-45779/TEV-45779 High Dose | 0/188 (0%) | 4/188 (2.1%) | 29/188 (15.4%) |
| Transition Period: TEV-45779/TEV-45779 Low Dose | 0/98 (0%) | 3/98 (3.1%) | 11/98 (11.2%) |
| Transition Period: XOLAIR/XOLAIR High Dose | 0/97 (0%) | 4/97 (4.1%) | 16/97 (16.5%) |
| Transition Period: XOLAIR/XOLAIR Low Dose | 0/51 (0%) | 0/51 (0%) | 8/51 (15.7%) |
| Transition Period: XOLAIR/TEV-45779 High Dose | 0/97 (0%) | 1/97 (1%) | 10/97 (10.3%) |
| Transition Period: XOLAIR/TEV-45779 Low Dose | 0/50 (0%) | 1/50 (2%) | 6/50 (12%) |
| Event | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|---|---|---|---|
| ColitisGastrointestinal disorders | 0/201 | 0/102 | 0/203 | 0/102 | 0/188 | 0/98 | 0/97 | 0/51 | 0/97 | 1/50 |
| EpiglottitisInfections and infestations | 0/201 | 0/102 | 0/203 | 0/102 | 0/188 | 0/98 | 1/97 | 0/51 | 0/97 | 0/50 |
| Pyelonephritis chronicInfections and infestations | 0/201 | 0/102 | 0/203 | 0/102 | 0/188 | 0/98 | 1/97 | 0/51 | 0/97 | 0/50 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/201 | 0/102 | 0/203 | 0/102 | 0/188 | 0/98 | 0/97 | 0/51 | 1/97 | 0/50 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/201 | 0/102 | 0/203 | 0/102 | 0/188 | 0/98 | 1/97 | 0/51 | 0/97 | 0/50 |
| UrticariaSkin and subcutaneous tissue disorders | 0/201 | 0/102 | 0/203 | 0/102 | 1/188 | 1/98 | 1/97 | 0/51 | 0/97 | 0/50 |
| Urinary tract infectionInfections and infestations | 0/201 | 0/102 | 0/203 | 0/102 | 0/188 | 1/98 | 0/97 | 0/51 | 0/97 | 0/50 |
| Back painMusculoskeletal and connective tissue disorders | 0/201 | 0/102 | 0/203 | 0/102 | 0/188 | 1/98 | 0/97 | 0/51 | 0/97 | 0/50 |
| CholelithiasisHepatobiliary disorders | 0/201 | 0/102 | 1/203 | 0/102 | 1/188 | 0/98 | 0/97 | 0/51 | 0/97 | 0/50 |
| ErysipelasInfections and infestations | 0/201 | 0/102 | 0/203 | 0/102 | 1/188 | 0/98 | 0/97 | 0/51 | 0/97 | 0/50 |
| Event | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Transition Period: TEV-45779/TEV-45779 High Dose | Transition Period: TEV-45779/TEV-45779 Low Dose | Transition Period: XOLAIR/XOLAIR High Dose | Transition Period: XOLAIR/XOLAIR Low Dose | Transition Period: XOLAIR/TEV-45779 High Dose | Transition Period: XOLAIR/TEV-45779 Low Dose |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 15/201 | 10/102 | 13/203 | 7/102 | 8/188 | 5/98 | 3/97 | 2/51 | 6/97 | 3/50 |
| Injection site painGeneral disorders | 13/201 | 9/102 | 11/203 | 5/102 | 8/188 | 3/98 | 2/97 | 2/51 | 1/97 | 2/50 |
| COVID-19Infections and infestations | 5/201 | 5/102 | 8/203 | 0/102 | 9/188 | 5/98 | 7/97 | 3/51 | 1/97 | 2/50 |
| Injection site indurationGeneral disorders | 12/201 | 6/102 | 12/203 | 5/102 | 7/188 | 3/98 | 3/97 | 1/51 | 3/97 | 3/50 |
| Injection site swellingGeneral disorders | 9/201 | 4/102 | 4/203 | 3/102 | 6/188 | 1/98 | 3/97 | 0/51 | 0/97 | 3/50 |
| Upper respiratory tract infectionInfections and infestations | 5/201 | 3/102 | 2/203 | 0/102 | 9/188 | 1/98 | 5/97 | 2/51 | 1/97 | 1/50 |
The intent-to-treat (ITT) analysis set included all randomized participants.
| Age, Continuous(years) | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Total |
|---|---|---|---|---|---|
| Mean | 41.1 ± 14.30 | 42.7 ± 13.64 | 42.0 ± 13.75 | 41.5 ± 14.29 | 41.7 ± 13.99 |
| Sex: Female, Male(Participants) | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Total |
|---|---|---|---|---|---|
| Female | 132 | 69 | 138 | 67 | 406 |
| Male | 69 | 33 | 65 | 35 | 202 |
| Ethnicity (NIH/OMB)(Participants) | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 45 | 13 | 26 | 11 | 95 |
| Not Hispanic or Latino | 153 | 88 | 174 | 89 | 504 |
| Unknown or Not Reported | 3 | 1 | 3 | 2 | 9 |
| Race/Ethnicity, Customized(Participants) | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Total |
|---|---|---|---|---|---|
| Race — American Indian/Alaskan/Native American | 12 | 4 | 4 | 0 | 20 |
| Race — Asian | 65 | 35 | 75 | 38 | 213 |
| Race — Black/African American | 0 | 3 | 2 | 0 | 5 |
| Race — White | 123 | 59 | 118 | 61 | 361 |
| Race — Other/Mixed | 1 | 0 | 3 | 2 | 6 |
| Race — Not Reported/Unknown | 0 | 1 | 1 | 1 | 3 |
| Weekly Itch Severity Score (ISS7)(units on a scale) | Main Treatment Period: TEV-45779 High Dose | Main Treatment Period: TEV-45779 Low Dose | Main Treatment Period: XOLAIR High Dose | Main Treatment Period: XOLAIR Low Dose | Total |
|---|---|---|---|---|---|
| Mean | 16.26 ± 3.721 | 16.14 ± 3.361 | 16.28 ± 3.524 | 16.00 ± 3.723 | 16.20 ± 3.590 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Apr 2024, 31 months.
Results were first posted in Oct 2025, 1 year 6 months after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 31 months is above that.
Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.